These data demonstrate that the PHD exerts an MPO-like activity, which induces bacterial death in a chloride-dependent manner. Furthermore, we found that the levels of oxidative damage of ingested bacteria as assessed on the basis of protein carbonylation and lipid peroxidation (13) were significantly reduced in the intestines of the dDuox-RNAi flies as compared with those seen in the bacteria from control intestines ( fig. S7 ). These results demonstrate that the infection-induced ROS generation by dDuox is responsible for the direct oxidative damage inflicted on ingested microbes.
These data demonstrate that the PHD exerts an MPO-like activity, which induces bacterial death in a chloride-dependent manner. Furthermore, we found that the levels of oxidative damage of ingested bacteria as assessed on the basis of protein carbonylation and lipid peroxidation (13) were significantly reduced in the intestines of the dDuox-RNAi flies as compared with those seen in the bacteria from control intestines ( fig. S7 ). These results demonstrate that the infection-induced ROS generation by dDuox is responsible for the direct oxidative damage inflicted on ingested microbes.
To demonstrate that the immune susceptibility of dDuox-RNAi flies could indeed be attributed to the insufficient enzymatic activity of Duox, we attempted to protect dDuox-RNAi flies by reintroducing a variety of Duox enzymes Ehuman Duox (hDuox) 1-2, dDuox, and dDuox-DPHD^ (Fig. 3A) . The reintroduction of both hDuox and dDuox, but not that of dDuox-DPHD, markedly augmented the survival rates of the dDuox-RNAi flies after natural infection (Fig. 3B) . These results are consistent with the previous observations ( Fig. 2D ), indicating that PHD is required for the microbicidal effects of Duox. The reduced levels of in vitro superoxide-producing activities and of in vivo intestinal ROS in the dDuox-RNAi flies were almost completely restored to normal levels by reintroducing the dDuox (Fig.  3 , C and D). Consistent with this, we detected that microbial persistence within the intestines of the dDuox-RNAi flies was reduced to control levels upon reintroduction of dDuox, but not upon dDuox-DPHD expression (Fig. 3E ). Taken together, our results demonstrated that intestinal dDuox is responsible for the generation of infection-induced microbicidal ROS and that ROS thus generated are required for limiting the proliferation of local pathogens during gut-microbe interactions.
ROS perform a variety of functions in many biological events, including host defense, development, hormone biosynthesis, fertilization, and diverse intracellular signaling (2-5, 14, 15, 22-28) . In the present study, we have demonstrated the in vivo role of Duox in innate immunity via mediating epithelial oxidative burst in Drosophila gut. Our study broadens the concept of ROS-based immunity by demonstrating that the oxidant-dependent defense system is not restricted to the phagocytes but rather is found in barrier epithelia. In addition to the NF-kB pathway-mediated defense system (7) (8) (9) (10) (11) , the Duox-mediated ROSdependent defense system involving both gp91 phox -like activity and MPO-like activity constitutes another microbicidal arm of Drosophila innate immunity. Further delineation of dDuox/IRC-mediated gastrointestinal redox homeostasis will provide important insight into innate immunity and the host-pathogen interaction. (4, 5) . In addition to Trp depletion, there is increasing evidence that catabolites of Trp assume an active role in dampening allogenic proliferation and inducing apoptosis of activated T cells (6, 7) . These catabolites, collectively referred to as kynurenines (Kyns), are important in the dialogue between the immune system and the central nervous system (CNS) (8) and have emerged as an attractive target for drug development (9, 10) .
In multiple sclerosis (MS) and its animal model, experimental autoimmune encephalomyelitis (EAE), autoreactive CD4 þ T H 1 cells secreting IFN-g and tumor necrosis factor (TNF) drive inflammation, which is amplified within the CNS by microglia (11) (12) (13) . Experimental therapeutic approaches aimed at skewing the cytokine profile of myelin-specific T H cells from T H 1 to T H 2 have included altered peptide ligands (APLs) (14, 15) , hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (Bstatins[), and DNA vaccination combined with gene delivery of interleukin 4 (IL-4) (16) (17) (18) . APLs are peptides modified at crucial receptor binding residues to modulate proliferation and the cytokine profile of antigen-specific T cells by altering the strength of T cell receptor (TCR) signaling (14) . Deviation of cytokine responses toward T H 2 is also a mechanism of action of glatriamer acetate, an example of an APL, which is an approved treatment for multiple sclerosis (19, 20) . Consequently, APLs inducing a T H 2 immune response have emerged as a potential therapeutic strategy to induce self-tolerance to autoantigens and to treat autoimmune diseases such as MS (21) (22) (23) (24) . Such approaches aimed at inducing a T H 2 shift have been relatively promising in reversing ongoing paralytic disease in the EAE model.
Initially, we aimed at identifying gene transcripts that are differentially regulated in T cells treated with APL. To do this, a T cell line generated from mice with a transgenic TCR specific for the myelin basic protein (MBP) peptide Ac1-11 was used for a gene microarray analysis (25) . The APL MBP Ac1-11E4Y^binds to the major histocompatibility complex (MHC) class II I-A u with greater affinity than the native peptide. MBP Ac1-11 induces primarily a T H 1 response, whereas MBP Ac1-11E4Y^promotes a T H 2 response (26) . Transcripts encoding IDO were more than 70-fold up-regulated after 48 hours in MBP Ac1-11E4Y^-activated T cells compared with MBP Ac1-11-activated cells (27) (table S1) . These data suggested a direct role of IDO in the tolerogenic effects of APLs.
We next tested the hypothesis that Trp metabolites (Kyns), generated by the enzymatic activity of IDO, play a role in regulating activation of myelin-specific T cells (25) . Splenocytes isolated from MBP Ac1-11 TCR transgenic B10.PL mice were stimulated with Proliferation and cytokine analysis were performed as described. Mean values and SEM of triplicates are given, and data are representative of two independent experiments. *P G 0.05, **P G 0.01.
MBP Ac1-11 in combination with the Trp metabolites picolinic acid (PA), quinolinic acid (QA), 3-hydroxyanthranilic acid (3-HAA), 3-hydroxykynurenic acid (3-HKA), and the synthetic derivative 3,4-DAA (25). 3,4-DAA was selected because it shares the anthranilic acid core with 3-HKA and 3-HAA (Fig. 1A) and because it is an orally active compound with favorable pharmacokinetics in humans (28). 3-HAA, 3-HKA, and 3,4-DAA suppressed antigen-specific proliferation of MBP Ac1-11 TCR transgenic CD4 þ T cells (Fig. 1B) . Suppression of T cell response by 3,4-DAA was associated with a G 1 /S-phase arrest in CD4 þ T cells rather than cytotoxic effects ( fig. S1 ). Both natural Trp metabolites and 3,4-DAA reduced the release of IL-2, IFN-g, and TNF-a from MBP Ac1-11 TCR transgenic T cells after antigen stimulation. Conversely, IL-4 and IL-10 were increased ( Fig. 1C; table S2 ). Thus, both natural Trp metabolites and 3,4-DAA skew the cytokine profile of these T cells from T H 1 to T H 2.
To examine the effects of 3,4-DAA on myelin-specific T cells in vivo, MBP Ac1-11 TCR transgenic mice were fed with 3,4-DAA for 5 days (25) (supporting online text, note S1). Splenocytes isolated from these animals showed reduced MBP Ac1-11-specific proliferation. Similarly, antigen-induced release of IFN-g, TNF-a, and IL-12/23 p40 was profoundly suppressed (Fig. 1D) , which indicates that 3,4-DAA is active when given orally to suppress the activation of autoreactive T H 1 cells.
Adaptive immunity in CD4 þ T H cells requires antigen presentation on MHC class II molecules and delivery of costimulatory signals via molecules such as CD40, CD80, and CD86, all inducible by IFN-g (29) . To assess the influence of Trp metabolites on antigen presentation, we used EOC20 microglial cells as a model (25) . EOC20 cells express MHC class II and costimulatory molecules constitutively at low levels, and these cells rapidly upregulate on exposure to IFN-g. 3,4-DAA decreased IFN-g-induced cell surface expression of MHC class II and costimulatory molecules ( Fig. 2A) (30) . 3,4-DAA-mediated suppression of IFN-g-induced MHC class II expression in EOC20 cells was paralleled by an inhibition of the MHC class II transactivator (CIITA) (Fig. 2B ). In addition, 3,4-DAA suppressed expression of inducible nitric oxide synthase (iNOS) and nitric oxide (NO) release from EOC20 cells induced by IFN-g and lipopolysaccharide (LPS) (Fig. 2, C and D) . On the basis of these results, we hypothesized that 3,4-DAA might interfere with IFN-g signaling: Type I and type II interferons predominantly signal through phosphorylation of signal transducer and activator of transcription (STAT) 1a (31) ; and consistent with the previous results, phosphorylation of STAT1a induced by IFN-g was suppressed after incubation with 3,4-DAA (Fig. 2E) . 3,4-DAA also suppressed the activation of APCs in vivo ( fig. S3, table S3 ).
To assess whether 3,4-DAA suppresses the function of autoreactive T H 1 cells, we tested the compound in vivo using the relapsingremitting version of EAE, which serves as a model of relapsing-remitting MS (25) . As patients with relapsing-remitting MS are typically treated after the first onset of clinical symptoms to prevent further attacks, we initiated treatment after the onset of disease. Although vehicle-treated animals displayed severe relapses throughout the course of disease, animals treated with 3,4-DAA had fewer and milder relapses and less severe disease (Fig.  3A) . At multiple dose levels, there was significant reduction in clinical disease index (CDI) and peak relapse score (table S4) .
Concordant with the capacity of 3,4-DAA to suppress activation of myelin-specific T H 1 cells in vitro, the frequency of activated T cells was decreased in mice treated with 3,4-DAA (Fig. 3B) . Moreover, PLP-specific T cell proliferation and the release of IFN-g, TNF-a, and IL-12/23 p40 were decreased after treatment with 3,4-DAA (Fig. 3C) (SOM text, note S2). Next, assessment of brains and spinal cords of mice with EAE revealed a reduction of parenchymal and total inflammatory foci in CNS tissue from mice treated with 3,4-DAA compared to vehicle-treated mice (Fig. 3D) .
We evaluated whether activation of APCs in the CNS was suppressed in vivo (25, 32) . Consistent with previous results, expression of MHC class II, CD40, CD80, CD86, and iNOS was drastically reduced in spinal cord microglial cells when mice with EAE had been treated with 3,4-DAA (Fig. 4A) . Moreover, the expression of the CIITA, iNOS, TNF-a, and IL-12/23 p40 genes was reduced in spinal cords of animals treated with 3,4-DAA (Fig.  4B) . Taken together, these results indicate suppression of APCs as a key mechanism underlying the immunosuppressive effects of 3,4-DAA. We finally assessed whether suppression of myelin specific T H 1 cells results from direct inhibition of these cells by 3,4-DAA, or whether this suppression might be mediated by myelin-specific T H 2-like cells induced by treatment with the drug (25) . Myelin-reactive lymph node cells from donor mice treated with 3,4-DAA after onset of EAE delayed the onset and ameliorated the symptoms of EAE when adoptively transferred into recipient mice that had been immunized with PLP p139-151 (Fig. 3E) . Finally, administration of either the natural Trp metabolite 3-HKA or the synthetic Trp metabolite 3,4-DAA to SJL mice with EAE induced release of IL-10 from PLP p139-151-reactive lymph node cells (Fig.  3F) (25) . Induction of IL-10 with these compounds in myelin-specific T cells was also observed in vitro (Fig. 1C) . Collectively, these data indicate that natural Trp metabolites induce antigen-specific IL-10-producing T cells with regulatory potential in vitro and in vivo. Moreover, these findings strongly suggest that 3,4-DAA, structurally related to Trp metabolites, has similar physiologic effects as well.
Interestingly, the structurally related immune regulators, linomide and laquinimod with a yet unidentified mechanism of action, are quinoline carboxamides with structural homology to these same Trp metabolites ( fig.  S5 ). Both linomide and laquinimod are effective in treating EAE and show some efficacy in patients with MS (33, 34) . Quinoline carboxamides, however, are cardiotoxic. Thus, trials of linomide in patients with MS have been halted. These observations further support our findings that Trp metabolites may represent a novel class of drugs effective in treating T H 1-mediated autoimmune diseases. Our results indicate that 3,4-DAA, by acting as a mimetic of the Trp catabolites, can replace the physiologic role of natural Trp catabolites in inhibiting autoreactive T H 1 cells. Orally active derivatives of Trp metabolites, such as 3,4-DAA, may thus represent a new class of drugs for therapy to treat ongoing T H 1-mediated autoimmune diseases. 
